BioMimetic Therapeutics, Inc. BMTI Securities Stock Fraud

Company:	BioMimetic Therapeutics, Inc.
Ticker Symbol:	BMTI
Class Period:	Oct-14-09 to May-11-11
Date Filed:	Jul-7-11
Lead Plaintiff Deadline:	Sep-5-11
Court:	---
Allegations:

New York, NY: A securities class action lawsuit has been filed on behalf of purchasers of BioMimetic Therapeutics, Inc. ("BMTI" or the "Company") common stock during the period from October 14, 2009 through May 11, 2011. No class has yet been certified.

The complaint asserts claims against BMTI and its officers and directors for violations of the federal securities laws. The complaint alleges that BMTI misrepresented the safety and efficacy of Augment and its prospects for FDA approval, and the inadequacies of Augment's clinical trials. On May 10, 2011, the FDA stated that there were material safety issues and questioned the benefits of Augment relative to its risks. As a result, BMTI's stock price dropped substantially, causing stockholders to suffer losses in their investments.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

BioMimetic Therapeutics, Inc. BMTI Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible BioMimetic Therapeutics, Inc. securities class action lawsuit. Please fill in our form on the right to submit your complaint for a free evaluation.